SB
ALNY icon

Suntrust Banks’s Alnylam Pharmaceuticals ALNY Stock Holding History

Suntrust Banks’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,198
Closed -$1.08M – 1230
2017
Q3 		$1.08M Buy
9,198
+5,178
+129% +$442K 0.01% 713
2017
Q2 		$321K Buy
+4,020
New +$257K ﹤0.01% 1019
2014
Q4 		– Sell
-3,714
Closed -$290K – 1171
2014
Q3 		$290K Sell
3,714
-146
-4% -$9.42K ﹤0.01% 1179
2014
Q2 		$243K Sell
3,860
-1,624
-30% -$96.5K ﹤0.01% 1292
2014
Q1 		$367K Buy
5,484
+1
+0% +$77 ﹤0.01% 1483
2013
Q4 		$352K Buy
5,483
+2
+0% +$119 ﹤0.01% 1441
2013
Q3 		$350K Buy
+5,481
New +$273K ﹤0.01% 1406

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM

Suntrust Banks's ALNY Position: Q4 2017 in Review

Suntrust Banks sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2017, closing a stake of 9,198 shares — an estimated $1.08M sold.

Suntrust Banks first reported a position in ALNY in Q3 2013 and held it in 7 quarters. The position peaked at $1.08M in Q3 2017. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

  • Suntrust Banks reported no remaining Alnylam Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Suntrust Banks sold 9,198 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $1.08M.
  • Suntrust Banks first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Suntrust Banks's Alnylam Pharmaceuticals position peaked at $1.08M in Q3 2017.
  • 282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Suntrust Banks's 13F filing for Q4 2017, filed 9 Feb 2018.